|
Expanding Cross-border Payment and Shariah-Compliant Solutions Across ASEAN
SINGAPORE, Nov. 13, 2025 /PRNewswire/ -- XTransfer, the world's leading B2B cross-border trade payment platform, and Maybank, a leading bank in ASEAN, are pleased to announce a strategic partnership to expand cross-border payment and Shariah-compliant solutions. Coinciding with Singapore FinTech Festival 2025, senior representatives of XTransfer and Maybank officially signed the Memorandum of Understanding (MOU) at the event.
Under the collaboration, XTransfer and Maybank will harness their respective strengths to deliver one-stop cross-border financial solutions, spanning domestic and cross-border payments and FX conversion, across key ASEAN markets, Hong Kong, United Kingdom and United States.
The parties will leverage new technologies and innovations, including APIs, digital platforms, collection solutions, and virtual accounts, to enable automated, real-time, and seamless FX conversion and transaction processing, enhancing the scalability, efficiency, and reliability of cross-border financial services.
Recognising the growing demand for Islamic finance-compliant services in ASEAN, XTransfer and Maybank will also explore and develop Shariah-compliant FX and payment offerings tailored to regional needs, broadening financial inclusion and meeting the evolving requirements of businesses seeking Shariah-compliant solutions.
This comprehensive partnership deepens XTransfer's Southeast Asia coverage and multi-currency settlement capabilities, while supporting Maybank's strategy to strengthen its regional franchise and ecosystem connectivity.
Bill Deng, Founder and CEO of XTransfer, said, "This collaboration with Maybank marks a significant step in elevating our services across ASEAN. With stronger local collection, FX conversion, and potential Shariah-compliant settlement capabilities, we will help businesses reduce costs, enhance cash flow, and improve transaction efficiency. We will continue to strengthen compliance and risk management to build a trusted cross-border financial infrastructure for our clients."
Dato' Sri Khairussaleh Ramli, President and Group CEO of Maybank (拿督斯里凯鲁沙烈, 总裁兼集团首席执行官 马来亚银行) said, "Together with XTransfer, we can enable more seamless cross-border payments and collections with competitive forex rates for merchants engaged in ASEAN-China trade, and participate in the surging flows between the two regions—now each other's largest trading partners. Total trade value is on track to reach USD1 trillion this year. This collaboration also opens opportunities to develop innovative solutions for businesses. With Maybank's presence in the key ASEAN markets, we are truly well positioned to support their cross-border needs."
Expanding Cross-border Payment and Shariah-Compliant Solutions Across ASEAN
SINGAPORE, Nov. 13, 2025 /PRNewswire/ -- XTransfer, the world's leading B2B cross-border trade payment platform, and Maybank, a leading bank in ASEAN, are pleased to announce a strategic partnership to expand cross-border payment and Shariah-compliant solutions. Coinciding with Singapore FinTech Festival 2025, senior representatives of XTransfer and Maybank officially signed the Memorandum of Understanding (MOU) at the event.
Under the collaboration, XTransfer and Maybank will harness their respective strengths to deliver one-stop cross-border financial solutions, spanning domestic and cross-border payments and FX conversion, across key ASEAN markets, Hong Kong, United Kingdom and United States.
The parties will leverage new technologies and innovations, including APIs, digital platforms, collection solutions, and virtual accounts, to enable automated, real-time, and seamless FX conversion and transaction processing, enhancing the scalability, efficiency, and reliability of cross-border financial services.
Recognising the growing demand for Islamic finance-compliant services in ASEAN, XTransfer and Maybank will also explore and develop Shariah-compliant FX and payment offerings tailored to regional needs, broadening financial inclusion and meeting the evolving requirements of businesses seeking Shariah-compliant solutions.
This comprehensive partnership deepens XTransfer's Southeast Asia coverage and multi-currency settlement capabilities, while supporting Maybank's strategy to strengthen its regional franchise and ecosystem connectivity.
Bill Deng, Founder and CEO of XTransfer, said, "This collaboration with Maybank marks a significant step in elevating our services across ASEAN. With stronger local collection, FX conversion, and potential Shariah-compliant settlement capabilities, we will help businesses reduce costs, enhance cash flow, and improve transaction efficiency. We will continue to strengthen compliance and risk management to build a trusted cross-border financial infrastructure for our clients."
Dato' Sri Khairussaleh Ramli, President and Group CEO of Maybank (拿督斯里凯鲁沙烈, 总裁兼集团首席执行官 马来亚银行) said, "Together with XTransfer, we can enable more seamless cross-border payments and collections with competitive forex rates for merchants engaged in ASEAN-China trade, and participate in the surging flows between the two regions—now each other's largest trading partners. Total trade value is on track to reach USD1 trillion this year. This collaboration also opens opportunities to develop innovative solutions for businesses. With Maybank's presence in the key ASEAN markets, we are truly well positioned to support their cross-border needs."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
XTransfer and Maybank Announce Strategic Partnership at Singapore FinTech Festival 2025
PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients. This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody–drug conjugates (ADCs) and other targeted therapeutics.
Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.
AJICAP™ technology is widely recognized for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end‑to‑end support, from early drug design and discovery through preclinical development.
Clients will benefit from NJ Bio's deep expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP™ platform. Based on prior technical experience working with AJICAP™ technology, NJ Bio anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes.
"Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio's mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs," said Julien Dugal-Tessier, the President and Chief Scientific Officer at NJ Bio. "This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP™ capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles."
"AJICAP™ was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. "Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients."
About NJ Bio, Inc.
NJ Bio, Inc. is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India. The company provides fully integrated chemistry and biology services to biotechnology and pharmaceutical companies, supporting programs from early discovery through GMP manufacturing. With deep expertise in bioconjugation, synthetic organic chemistry, protein‑based biopharmaceuticals, and GMP manufacturing, it specializes in ADCs, targeted protein degraders (TPDs), oligo‑conjugates, and other non‑oncology conjugated therapeutics. The organization delivers customized, science‑driven solutions designed to accelerate development timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more: https://njbio.com/
About Ajinomoto Bio‑Pharma Services
Ajinomoto Bio‑Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical and pilot programs through commercial supply—including high‑potency APIs (HPAPI), continuous‑flow manufacturing, oligonucleotide synthesis, biocatalysis, CORYNEX® protein expression technology, and antibody–drug conjugation (ADC) services. Learn more: https://ajibio-pharma.ajinomoto.com
For further information, please contact: HERE
Photo - https://mma.prnasia.com/media2/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
